Avanos Medical (AVNS) Q3 Earnings and Revenues Beat Estimates

Core Insights - Avanos Medical reported quarterly earnings of $0.22 per share, exceeding the Zacks Consensus Estimate of $0.16 per share, but down from $0.36 per share a year ago, representing an earnings surprise of +37.50% [1] - The company achieved revenues of $177.8 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 6.88% and up from $170.4 million year-over-year [2] Financial Performance - Over the last four quarters, Avanos Medical has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] - The current consensus EPS estimate for the upcoming quarter is $0.29 on revenues of $176.14 million, and for the current fiscal year, it is $0.92 on revenues of $684.98 million [7] Market Position - Avanos Medical shares have declined approximately 29% since the beginning of the year, contrasting with the S&P 500's gain of 15.1% [3] - The Zacks Industry Rank places the Medical - Instruments sector in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] Future Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current Zacks Rank for Avanos Medical is 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6]